fulphila 6 mg/0.6 ml s.c. pref. syringe
فولفيلا 6 مجم 0.6مل سرنجة معبأة
pegfilgrastimThe published official price. Pharmacies may differ slightly.
- Strength
- 6 mg/0.6 ml
- Form
- syringe
- Manufacturer
- one pharma medics
- Route
- injection
The medical information below is guidance and may be incomplete or wrong. Do not change your medicine or dose based on it — ask a pharmacist or doctor.
Uses
Pegfilgrastim is a pegylated granulocyte colony-stimulating factor (G-CSF) indicated to reduce the incidence of febrile neutropenia in adults and pediatric patients with non-myeloid malignancies receiving myelosuppressive anticancer chemotherapy.
Do not use if
Contraindicated in patients with a history of serious hypersensitivity reactions to pegfilgrastim or filgrastim products, including anaphylaxis.
Side effects
Common side effects include bone pain, musculoskeletal pain, and headache. Serious adverse reactions include splenic rupture, acute respiratory distress syndrome (ARDS), serious hypersensitivity reactions including anaphylaxis, and sickle cell crisis in susceptible patients.
Warnings
Monitor for splenic rupture if left upper abdominal or shoulder pain occurs. Evaluate for ARDS if fever, lung infiltrates, or respiratory distress develop. Use with caution in patients with sickle cell disorders. Avoid simultaneous use with myelosuppressive chemotherapy.
How it works
Pegfilgrastim binds to specific cell surface receptors on hematopoietic cells, stimulating proliferation, differentiation, and functional activation of neutrophil precursors. Pegylation extends the half-life compared to filgrastim by reducing renal clearance.
Storage
Store refrigerated at 2°C to 8°C in the original carton to protect from light. Do not freeze; if accidentally frozen, thaw in the refrigerator before use. Discard if stored at room temperature for more than 15 days.